RTP Mobile Logo
Submitted by nenadkesic@gmail.com on Tue, 12/19/2017 - 11:18
ONUL117

Interview with Matthew Gubens, MD, MS

 

Track 1: Case: A 79-year-old man and former smoker with KRAS mutation-positive metastatic adenocarcinoma of the lung receives second-line treatment with nivolumab
Track 2: Incidence, monitoring and management of immune checkpoint inhibitor-associated pneumonitis
Track 3: PACIFIC: A Phase III trial of durvalumab after chemoradiation therapy for Stage III non-small cell lung cancer (NSCLC)
Track 4: Treatment options for patients with locally advanced NSCLC and rapid disease progression
Track 5: Pseudoprogression in patients receiving immune checkpoint inhibitors
Track 6: Immune checkpoint inhibitor-associated side effects
Track 7: Use of immune checkpoint inhibitor therapy for patients with preexisting autoimmune disorders
Track 8: Case: A 51-year-old woman and previous smoker with metastatic adenocarcinoma of the lung and no actionable mutations responds to pembrolizumab and carboplatin/pemetrexed on the Phase II KEYNOTE-021 trial
Track 9: Approach to first-line therapy for patients with newly diagnosed, mildly symptomatic adenocarcinoma of the lung and a high PD-L1 tumor proportion score (TPS)
Track 10: Therapeutic options for patients with a PD-L1 TPS of 1% to 49%
Track 11: Choosing between pembrolizumab alone or in combination with carboplatin/pemetrexed as first-line therapy for metastatic nonsquamous NSCLC
Track 12: Single-agent pembrolizumab as first-line therapy for patients with advanced NSCLC and a high PD-L1 TPS
Track 13: Immune checkpoint inhibitor-associated cellulitis and conjunctivitis
Track 14: Decision-making about the discontinuation of immune checkpoint inhibitor therapy after a prolonged response
Track 15: MYSTIC trial: Lack of progression-free survival (PFS) benefit with durvalumab/tremelimumab versus platinum-based chemotherapy for previously untreated metastatic NSCLC
Track 16: Nivolumab/ipilimumab as second-line therapy for small cell lung cancer (SCLC)
Track 17: Potential benefit of immune-directed therapies for patients with preexisting paraneoplastic syndromes
Track 18: Case: A 77-year-old woman and never smoker with ALK-rearranged metastatic adenocarcinoma of the lung experiences disease progression on third-line alectinib
Track 19: Resolution of choroidal metastases with crizotinib
Track 20: Testing for specific gene mutations to direct up-front targeted therapy for adenocarcinoma of the lung
Track 21: Therapeutic options for patients with ALK-rearranged advanced NSCLC and disease progression on crizotinib
Track 22: Clinical utility of FDA-approved (alectinib, brigatinib, ceritinib) and investigational (lorlatinib) ALK inhibitors in advanced NSCLC
Track 23: Case: A 74-year-old man and never smoker with EGFR exon 19 mutation-positive adenocarcinoma of the lung and multifocal brain metastases receives osimertinib
Track 24: First-line erlotinib versus afatinib or gefitinib for EGFR-mutated metastatic NSCLC
Track 25: Identification of T790M EGFR resistance mutations in NSCLC
Track 26: Utility of osimertinib for patients with advanced NSCLC who acquire the T790M EGFR mutation
Track 27: BLOOM: Activity of osimertinib in patients with leptomeningeal disease from EGFR-mutated advanced NSCLC in a Phase I study
Track 28: Activity of osimertinib in patients with T790M mutation-positive advanced NSCLC and brain metastases
Track 29: Mechanism of action and efficacy of the antibody-drug conjugate rovalpituzumab tesirine (Rova-T) in DLL3-expressing recurrent SCLC

Interview with Suresh S Ramalingam, MD

Track 1: Case: An 83-year-old woman and never smoker with EGFR exon 19 mutation-positive advanced adenocarcinoma of the lung acquires a T790M mutation
Track 2: Selection among available EGFR tyrosine kinase inhibitors (TKIs) as first-line therapy for EGFR mutation-positive NSCLC
Track 3: Tolerability of osimertinib compared to erlotinib
Track 4: FLAURA study results: Osimertinib versus erlotinib or gefitinib as first-line therapy for EGFR-mutated advanced NSCLC
Track 5: Antitumor activity and no evidence of acquired EGFR T790M mutation after disease progression with osimertinib as first-line therapy for EGFR-mutated advanced NSCLC on the Phase I/II AURA trial
Track 6: Plasma testing for T790M mutations
Track 7: Design of the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST) for patients with early-stage disease
Track 8: ADJUVANT (CTONG 1104): Initial results of a Phase III trial evaluating adjuvant gefitinib or vinorelbine/platinum for EGFR mutation-positive Stage II to IIIA NSCLC
Track 9: Case: A 63-year-old woman with ALK-rearranged metastatic NSCLC who had to discontinue crizotinib/immune checkpoint inhibitor therapy on a clinical trial subsequently receives alectinib
Track 10: Overview of the activity of available ALK inhibitors
Track 11: Efficacy and tolerability of brigatinib
Track 12: Second-line therapeutic options for patients with ALK-rearranged NSCLC
Track 13: Alectinib versus crizotinib for ALK-rearranged NSCLC
Track 14: Case: A 64-year-old woman with concurrent ER/PR-negative, HER2-positive breast cancer and BRAF V600E-mutated adenocarcinoma of the lung
Track 15: Dabrafenib/trametinib for BRAF V600E mutation-positive metastatic NSCLC
Track 16: Case: A 63-year-old man with metastatic squamous cell NSCLC and Type 2 diabetes receives carboplatin/nab paclitaxel followed by second-line atezolizumab
Track 17: Second-line immunotherapy options for patients with metastatic squamous cell NSCLC
Track 18: Necitumumab or docetaxel/ramucirumab as second-line treatment for advanced squamous cell NSCLC
Track 19: Using metaphors to explain molecular testing to patients with cancer
Track 20: Biology of resistance to TKIs in patients with EGFR mutations
Track 21: ECOG-ACRIN 2511: A Phase I/II study of cisplatin and etoposide with or without the PARP inhibitor veliparib as front-line therapy for extensive-stage SCLC
Track 22: Rova-T in DLL3-positive SCLC
Track 23: Activity of combined anti-PD-1 and anti-CTLA-4 inhibitors in SCLC
Track 24: Toxicity comparison of anti-PD-1 and anti-PD-L1 antibodies
Track 25: Cardiac allograft rejection as a complication of PD-1 checkpoint blockade
Track 26: Safety of immune checkpoint inhibitors for patients who have undergone organ transplants
Track 27: Rationale for combining the anti-CD38 antibody daratumumab with immune checkpoint inhibitors for NSCLC
Track 28: First-line pembrolizumab compared to chemotherapy for patients with PD-L1-positive NSCLC
Track 29: Duration of response to first-line pembrolizumab
Track 30: First-line carboplatin/pemetrexed/pembrolizumab for advanced nonsquamous NSCLC
Track 31: Choosing between pembrolizumab monotherapy and pembrolizumab with chemotherapy for patients with advanced NSCLC
Track 32: Molecular testing algorithm for patients with nonsquamous NSCLC
Track 33: Biologic background of the activity of immune checkpoint inhibitors in patients with NSCLC and driver mutations
Track 34: Meta-analysis comparing the efficacy of immune checkpoint inhibitors to that of chemotherapy in patients with EGFR wild-type versus mutated NSCLC
 
FACULTY
 
Matthew Gubens, MD, MS
Associate Professor
Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California
 
Suresh S Ramalingam, MD
Professor of Hematology and
Medical Oncology
Assistant Dean for Cancer Research
Emory University School of Medicine
Deputy Director
Winship Cancer Institute
Atlanta, Georgia
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida